Science
David Sinclair plans to test whole-body rejuvenation drugs in the XPrize competition
The longevity researcher will conduct human trials of an oral "reprogramming" drug as part of a $101 million competition. The approach aims to reverse cellular aging through epigenetic reprogramming, though significant scientific challenges remain.
Read full story at MIT Technology Review →V: · A: · D:
Related
Science
Using AI to help physicians diagnose rare genetic diseases affecting children
Researchers used an OpenAI reasoning model to identify 18 new diagnoses in previously unsolved cases of rare childhood g...
Science
The search for dark matter has been blown wide open
Decades of searching for weakly interacting massive particles have produced no detection, and physicists are now serious...
Science
A near-autonomous AI chemist improves a challenging reaction in medicinal chemistry
OpenAI and Molecule.one report that a near-autonomous AI system using GPT-5.4 was able to improve a difficult reaction i...